# Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant

> **NCT03537599** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sumithira Vasu** · enrollment: 4 (actual)

## Conditions studied

- Minimal Residual Disease
- Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes
- Recurrent Adult Acute Myeloid Leukemia
- Recurrent Childhood Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** Daratumumab
- **PROCEDURE:** Donor Lymphocyte Infusion
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT03537599
- **Lead sponsor:** Sumithira Vasu
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-10
- **Primary completion:** 2021-08-04
- **Final completion:** 2022-02-03
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Poor acccrual
- **Last updated:** 2025-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03537599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03537599, "Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03537599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*